Following a Bachelor's and a Master’s degree in Biochemistry, I carried out by doctoral studies in Bharathiar University, India in collaboration with National Dong Hwa University, Taiwan, studying molecular mechanisms involved in combination therapy of neferine and doxorubicin to induce autophagy and apoptosis in lung cancer cells. Then I have relocated to United Kingdom to pursue my postdoctoral fellowship in cancer. At the University of Liverpool, I studied the apoptosis mechanisms induced by maritoclax and Dinaciclib. Further in Bangor University, I have worked on the cellular uptake mechanism and anticancer efficiency of nitro-reductase coated gold magnetic nanoparticles for directed enzyme prodrug therapy (DEPT) in ovarian cancer cells. Currently, I am studying the role of NRF2 in ErbB targeted therapy in breast cancer cells.

Senior Research Fellow, Council of Scientific and Industrial Research, India, 2012

Junior Research Fellow, Department of Science and technology, India and National Science Council, Taiwan, 2010

Award for academic excellence, Avinashilingam University, India, 2008

Award for academic excellence, Bharathiar University, India, 2006

Invited talks

Resource person: “Role of NRF2 in drug resistance and cancer therapy” in the international conference on Biozone 2018 -Current trends in cancer research and therapeutics, Sacred Heart College, Thiruvalluvar University, India; 2018

Resource person: “NRF2 in chemo-resistance” in the lecture series on cancer at Sree Ramakrishna College of Arts and Science for Women, Bharathiar University, India; 2018

Resource person: “Targeting the shadows of redox modulating NRF2 to combat drug resistance in cancer” in the Technical seminar on cancer at Sree Narayana Guru College of Arts and Science, Bharathiar University, India; 2018

Keynote speaker: “Neferine as a double-edged sword towards doxorubicin resistance and cardiotoxicity” in the International conference of translational medicine at Institute of Biotechnology, National Dong Hwa University, Taiwan; 2011

Outreach

“A role for NRF-2 in the mechanism of action and effectiveness of dual tyrosine kinase inhibitor, lapatinib, in breast cancer cells” at 2018 NCRI Cancer Conference, taking place on at the Scottish Event Campus, Glasgow, UK; 2018